tafamidis
Selected indexed studies
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. (N Engl J Med, 2018) [PMID:30145929]
- Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. (Circ Heart Fail, 2022) [PMID:34923848]
- Tafamidis. (, 2012) [PMID:40043215]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. (2018) pubmed
- Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. (2022) pubmed
- Tafamidis. (2012) pubmed
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. (2021) pubmed
- Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. (2012) pubmed
- Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy. (2021) pubmed
- Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. (2024) pubmed
- Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS). (2025) pubmed
- Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. (2024) pubmed
- Tafamidis for the treatment of transthyretin amyloidosis. (2019) pubmed